Influenza Vaccine Revaccination in Ambulatory Elderly Subjects
NCT00775450
Completed
This is a multi-center study designed to evaluate the safety and immunogenicity of a Fluzone revaccination in elderly adults aged ≥ 65 years. Primary Objective: To describe the safety profile for all subjects. Secondary Objective: To describe immunogenicity 28 days following revaccination with one of three Fluzone formulations.
Gender:
ALL
Ages:
65 years and above
Trial Updated:
12/05/2013
Locations: Not set, Cary, North Carolina +1 locations
Conditions: Influenza, Orthomyxovirus Infection, Myxovirus Infection
Register for Updates
Study to Evaluate the Safety of Novartis MenACWY Conjugate Vaccine When Administered With Routine Infant Vaccinations to Healthy Infants
NCT00806195
Completed
The primary objective of this phase 3b study is to evaluate the safety and tolerability of Novartis MenACWY conjugate vaccine when administered with routine infant vaccinations to healthy infants
Gender:
ALL
Ages:
Between 55 days and 89 days
Trial Updated:
05/13/2013
Locations: 56 Cary Pediatrics 1001 Crescent Green Dr., Cary, North Carolina +6 locations
Conditions: Meningitis, Meningococcal Infection
Register for Updates
Immunogenicity of a Split, Cell-Based, Inactivated, Trivalent Influenza Vaccine in Healthy Adult Subjects
NCT00845429
Completed
Primary Objective: To describe the immune response to a single administration of 2 formulations of the investigational cell-based influenza vaccines in healthy adult subjects. Secondary Objective: To describe the safety following a single administration of 2 formulations of the investigational cell-based influenza vaccines in healthy adult subjects.
Gender:
ALL
Ages:
Between 18 years and 49 years
Trial Updated:
12/13/2012
Locations: Not set, Cary, North Carolina +1 locations
Conditions: Influenza, Orthomyxoviruses, Myxovirus Infection
Register for Updates
Multi-Year Study of Fluzone High-Dose Influenza Vaccine Compared With Fluzone® Vaccine in Adults Aged 65 Years and Older
NCT00976027
Terminated
The aim of this study is to determine the efficacy of Fluzone High Dose vaccine and that of Fluzone® vaccine in the elderly. Primary objective: To measure the efficacy of the vaccine, defined as the prevention of laboratory-confirmed influenza caused by viral types/subtypes that are antigenically similar to those contained in the respective annual vaccine formulations. Secondary objectives: * To compare the clinical efficacy of Fluzone High Dose vaccine with that of Fluzone® vaccine in elder... Read More
Gender:
ALL
Ages:
65 years and above
Trial Updated:
07/24/2012
Locations: Not set, Cary, North Carolina +7 locations
Conditions: Influenza
Register for Updates
NicVAX/Placebo as an Aid for Smoking Cessation
NCT00836199
Completed
The purpose of this study is to evaluate NicVAX as an aid to smoking cessation for long term abstinence.
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
05/08/2012
Locations: NicVAX Investigator, Raleigh, North Carolina
Conditions: Smoking Cessation, Smoking, Tobacco Cessation
Register for Updates
Double Blind, Safety and Immunogenicity Study of Recombinant Botulinum Vaccine A/B
NCT00764634
Completed
This Phase 2 study is a double blind, placebo-controlled, randomized, multicenter investigation of rBV A/B-40 vaccine or placebo in healthy adults, using two different three-dose dosing schedules.
Gender:
ALL
Ages:
Between 18 years and 55 years
Trial Updated:
11/28/2011
Locations: Wake Research Associates, Raleigh, North Carolina
Conditions: Botulism Vaccine
Register for Updates
A Study of Different Formulations of an Adjuvanted A/H1N1 Pandemic Vaccine in Healthy Adults and the Elderly
NCT00952276
Completed
The purpose of the study is to evaluate different doses of the Influenza A/H1N1 pandemic vaccine in adults and the elderly. Primary Objectives: * To describe the immunogenicity of the candidate vaccines after a single injection. * To describe the safety of the candidate vaccines after a single injection.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/26/2011
Locations: Not set, Raleigh, North Carolina
Conditions: Influenza, Swine-origin A/H1N1 Influenza
Register for Updates
Study Evaluating the Safety, Tolerability and Immunogenicity of 13vPnC as a 2-Dose Regimen or With 23vPS
NCT00574548
Completed
The objective of this study is to compare the safety, tolerability and immunologic response to a dose of 23vPS or 13vPnC given one year after either 13vPnC or 23vPS in subjects that have never received a previous dose of 23vPS.
Gender:
ALL
Ages:
Between 60 years and 64 years
Trial Updated:
07/18/2011
Locations: Pfizer Investigational Site, Raleigh, North Carolina
Conditions: Pneumococcal Vaccines
Register for Updates